Medical Cyclotron Market Surging at 5.5 percent CAGR to Reach USD 188.32 Million by 2032 Fuelled by Rising Dema - Benzinga
| EDT Stock | CAD 0.57 0.02 3.64% |
About 55% of Spectral Med's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Spectral Med suggests that some traders are interested. Spectral Med's investing sentiment overview a quick insight into current market opportunities from investing in Spectral Med. Many technical investors use Spectral Med stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Spectral |
Medical Cyclotron Market Surging at 5.5 percent CAGR to Reach USD 188.32 Million by 2032 Fuelled by Rising Dema Benzinga
Read at news.google.com
 |
Spectral Med Fundamental Analysis
We analyze Spectral Med's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Spectral Med using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Spectral Med based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Spectral Med is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Spectral Med Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Spectral Med stock to make a market-neutral strategy. Peer analysis of Spectral Med could also be used in its relative valuation, which is a method of valuing Spectral Med by comparing valuation metrics with similar companies.
Peers
Spectral Med Related Equities
| MBX | Microbix Biosystems | 2.38 | ||||
| MDNA | Medicenna Therapeutics | 0.67 | ||||
| APS | Aptose Biosciences | 2.94 | ||||
| HBP | Helix BioPharma | 3.23 |
Other Information on Investing in Spectral Stock
Spectral Med financial ratios help investors to determine whether Spectral Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Spectral with respect to the benefits of owning Spectral Med security.